Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study

Abstract Background Direct-acting antiviral agents (DAAs) have shown high rates of sustained virological response in chronic hepatitis C virus (HCV) infection. However, the influence of DAAs on the course of kidney involvement in HCV-associated mixed cryoglobulinaemia (HCV-MC) has been little studie...

Full description

Saved in:
Bibliographic Details
Published in:Clinical Kidney Journal 2021-02, Vol.14 (2), p.586-592
Main Authors: Pérez de José, Ana, Carbayo, Javier, Pocurull, Anna, Bada-Bosch, Teresa, Cases Corona, Clara Maria, Shabaka, Amir, Ramos Terrada, Natàlia, Martinez Valenzuela, Laura, Huerta, Ana, Fernandez Lorente, Loreto, Malek-Marín, Tamara Gelen, Goicoechea, Marian
Format: Article
Language:English
Subjects:
B cells
Biological response modifiers
Care and treatment
Health aspects
Hepatitis C virus
Infection
Interferon
Medical research
Medicine, Experimental
Mortality
Original
Prognosis
Spain
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Direct-acting antiviral agents (DAAs) have shown high rates of sustained virological response in chronic hepatitis C virus (HCV) infection. However, the influence of DAAs on the course of kidney involvement in HCV-associated mixed cryoglobulinaemia (HCV-MC) has been little studied. The aim of this study was to analyse the effects of antiviral treatment on kidney prognosis and evolution in patients diagnosed with HCV-MC. Methods The RENALCRYOGLOBULINEMIC study is an observational multicentre cohort study of 139 patients with HCV-MC from 14 Spanish centres. Clinical and laboratory parameters were measured before and after antiviral treatment. Primary endpoints were kidney survival and mortality after HCV-MC diagnosis. Secondary endpoints were clinical, immunological and virological responses after antiviral treatment. Results Patients were divided into three groups based on the treatment received: treatment with DAAs (n = 100) treatment with interferon (IFN) and ribavirin (RBV) (n = 24) and no treatment (n = 15). Patients were followed up for a median duration of 138 months (interquartile range 70–251. DAA treatment reduced overall mortality {hazard ratio [HR] 0.12 [95% confidence interval (CI) 0.04–0.40]; P 
ISSN:2048-8505
2048-8513
DOI:10.1093/ckj/sfz178